Why I’d avoid this dividend-raising FTSE 250 stock and what I’d buy instead

This company just raised its dividend for the 17th consecutive time. But I see a problem.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Given the state of the general stock market this morning, it’s no surprise to see the Clarkson (LSE: CKN) share price down nearly 7% today, as I write. I reckon three things could be affecting the shipping services stock.

First, it’s probably dropping because of general uncertainties and sentiment about the COVID-19 coronavirus and how the outbreak might affect the world economy. Second, shares often fall on the day a company releases its full-year results report. Unless there’s outstanding and unexpected good news in the report, falling on the day is often a ‘thing’.

And the third possibility is that the report may contain some negative news that the market wasn’t expecting or which wasn’t already baked into the share price. Let’s dig in to find out.

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

A short-term hit to business

There is indeed a negative. Chief executive Andi Case said in the report that Covid-19 will “impact” the firm’s first-half performance in 2020. So, there are no ifs or buts about that. The coronavirus is causing real economic damage to companies such as Clarkson. This makes me believe the stock market is being rational with its bearish recent moves.

However, Case goes on to say that the company started 2020 with a stronger order book than the year before. And over the medium term, he reckons the “environmental regulatory drivers and supply demand dynamics in the shipping industry are favourable” and he has “confidence” in the firm’s prospects.

But I reckon the company’s niche in the market is highly cyclical. Clarkson says its integrated services and investment banking capabilities to the shipping and offshore markets facilitate global trade. And to me, that means the company’s fortunes are dependent on global trade and the entrepreneurial efforts of others. In that respect, its business reminds me of big banks such as Lloyds, Barclays and HSBC. These also facilitate the business of others.

Good figures

For what it’s worth, in 2019, revenue rose 7.5% compared to the prior year and underlying earnings per share increased by 13%. The directors pushed up the total dividend for the year by 4%, the 17th consecutive dividend rise. That’s a great achievement. But I wouldn’t look at Clarkson as a dividend-led investment and buy the stock purely to harvest that income stream.

The reason is that although the share price has risen a lot over the past 17 years, it’s been moving essentially sideways for the past six or so. And I reckon that’s probably happened because Clarkson has an over-valuation problem. Indeed, with the share price near 2,275p, the forward-looking earnings multiple is just under 18 for 2020 and the anticipated dividend yield is 3.6%.

Meanwhile, City analysts have pencilled in a low, double-figure percentage increase in earnings for the current trading year. But I reckon if a global downturn really gains traction, revised, lower forecasts could leave the valuation looking even loftier. In a scenario like that, I can only imagine the share price moving lower.

My conclusion is the same as it was a year ago: I’d rather invest in a FTSE 250 tracker fund than in Clarkson.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended Barclays, HSBC Holdings, and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

How a stock market crash could boost investors’ passive income by over 40%

Jon Smith explains how a continued fall in the stock market isn't always a bad thing, especially when it comes…

Read more »

Investing Articles

If an investor put £10k into Greggs shares one month ago, here’s what they’d have today

Greggs shares have had a tough year but Harvey Jones says they're notably cheaper as a result, while the dividend…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Phoenix share price jumps 7.5% on today’s results, but still yields a stunning 9.4%!

Harvey Jones put his faith in the Phoenix share price and this morning was rewarded with a 7.5% jump on…

Read more »

Investing Articles

What’s been going on with the Barclays share price?

The rising Barclays share price reflects confidence in management’s strategy to improve business performance and enhance shareholder returns.

Read more »

Investing Articles

Prediction: in 1 year, the IAG share price could reach as high as…

The IAG share price has almost doubled in the last 12 months, but can this momentum continue in 2025? Zaven…

Read more »

Investing Articles

Prediction: in 12 months, here’s where the Glencore share price could be…

The performance of Glencore’s share price has been lacklustre, to say the least. But could all that change over the…

Read more »

Investing Articles

See how much an investor needs in their ISA to earn a £499 monthly second income

Harvey Jones crunches the numbers to show how it's possible to build a long-term second income by investing in a…

Read more »

Investing Articles

I’m considering buying more of this struggling FTSE 100 stock

This FTSE 100 stock hasn't exactly set our writer's portfolio on fire during the time he's owned it. But Paul…

Read more »